# Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

> **NCT03971461** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 32 (actual)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** Lutathera

## Key facts

- **NCT ID:** NCT03971461
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-15
- **Primary completion:** 2025-04-18
- **Final completion:** 2027-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971461, "Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03971461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*